GE stock up 9% after $21 billion biopharma sale to Danaher
General Electric stock is up after a blockbuster sale of its biopharmaceutical division.
Why is GE’s stock up?
GE's shares are up after the corporation sold its biopharma unit to Danaher to help lessen its $100 billion debt. The deal will give GE much needed cash to pay its insurance liabilities as well. The biopharmaceutical division of the company makes software to support drug research. The GE Life Sciences division will combine with Danaher’s Life Science section.
The biopharma section comprises 15% of the corporation and is one of the most profitable. The subdivision is expected to bring in $3.2 billion by the end of the year to increase the company’s profits. GE chief executive officer, (CEO), Larry Culp, said that the sale will help the conglomerate focus on its core business of plane engines and power plants.
‘We are focused on completing the carve out [of the biopharma business] – which is 15% of the $20 billion healthcare segment – and focused on managing the remaining core business,’ said Culp.
‘It demonstrates that we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and strengthen our balance sheet,’ added Culp.
William and Co. banking analyst, Nicolas Heymann, prasied the deal that lifted GE shares.
‘The price Danaher is paying GE is two times our[William and Co’s] expectations. This is a home run. It really turns the page now for GE to address liquidity concerns,’ said Heymann.
What’s next for GE’s shares?
GE’s partnership with Danaher may be a continuation of a positive streak for the company’s stock. The corporation’s Q4 report was better-than-expected and has led to an upswing in GE's stock. GE’s share price could continue to surge if the conglomerate continues to make major deals like its current sale to Danaher.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.